Novartis Certican “approvable”
Executive Summary
Novartis is in the process of collecting additional clinical data to submit to FDA following receipt of "approvable" letter for Certican Oct. 20. Company says it does not expect to have to conduct additional clinical trials before approval. Everolimus NDA seeks combination use with cyclosporine for the prevention of rejection episodes following heart or kidney transplantation...